IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Stock Holdings Reduced by Teacher Retirement System of Texas

Teacher Retirement System of Texas lowered its stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYAFree Report) by 25.5% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 10,242 shares of the company’s stock after selling 3,499 shares during the period. Teacher Retirement System of Texas’ holdings in IDEAYA Biosciences were worth $364,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in IDYA. Fisher Asset Management LLC lifted its position in shares of IDEAYA Biosciences by 1,609.8% in the fourth quarter. Fisher Asset Management LLC now owns 539,025 shares of the company’s stock worth $19,179,000 after buying an additional 507,500 shares during the last quarter. Federated Hermes Inc. lifted its position in shares of IDEAYA Biosciences by 14.8% in the fourth quarter. Federated Hermes Inc. now owns 3,883,775 shares of the company’s stock worth $138,185,000 after buying an additional 500,046 shares during the last quarter. Victory Capital Management Inc. acquired a new stake in shares of IDEAYA Biosciences in the fourth quarter worth about $12,328,000. Eventide Asset Management LLC acquired a new stake in shares of IDEAYA Biosciences in the third quarter worth about $9,038,000. Finally, Charles Schwab Investment Management Inc. lifted its position in shares of IDEAYA Biosciences by 199.3% in the third quarter. Charles Schwab Investment Management Inc. now owns 437,356 shares of the company’s stock worth $11,800,000 after buying an additional 291,240 shares during the last quarter. Institutional investors and hedge funds own 98.29% of the company’s stock.

IDEAYA Biosciences Stock Down 0.5 %

Shares of IDYA opened at $37.53 on Wednesday. IDEAYA Biosciences, Inc. has a 12-month low of $20.90 and a 12-month high of $47.74. The firm has a market capitalization of $2.84 billion, a price-to-earnings ratio of -18.67 and a beta of 0.83. The stock’s 50-day moving average price is $41.22 and its 200 day moving average price is $39.68.

IDEAYA Biosciences (NASDAQ:IDYAGet Free Report) last released its quarterly earnings data on Tuesday, May 7th. The company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.02). IDEAYA Biosciences had a negative net margin of 483.05% and a negative return on equity of 20.09%. During the same period in the prior year, the business earned ($0.49) earnings per share. The business’s quarterly revenue was down 100.0% on a year-over-year basis. Equities research analysts expect that IDEAYA Biosciences, Inc. will post -2.36 EPS for the current year.

Analysts Set New Price Targets

A number of analysts have weighed in on the company. Leerink Partnrs reaffirmed an “outperform” rating on shares of IDEAYA Biosciences in a research report on Friday, February 23rd. Royal Bank of Canada boosted their price objective on IDEAYA Biosciences from $43.00 to $53.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 21st. JPMorgan Chase & Co. boosted their price objective on IDEAYA Biosciences from $51.00 to $57.00 and gave the stock an “overweight” rating in a research report on Friday, February 23rd. Capital One Financial reissued an “overweight” rating on shares of IDEAYA Biosciences in a research report on Thursday, February 22nd. Finally, The Goldman Sachs Group cut their price objective on IDEAYA Biosciences from $53.00 to $46.00 and set a “buy” rating for the company in a research report on Monday, May 13th. Twelve research analysts have rated the stock with a buy rating, According to MarketBeat, IDEAYA Biosciences has a consensus rating of “Buy” and an average target price of $46.80.

Check Out Our Latest Report on IDEAYA Biosciences

Insider Activity

In other news, CEO Yujiro S. Hata sold 56,711 shares of the company’s stock in a transaction that occurred on Tuesday, May 14th. The stock was sold at an average price of $41.61, for a total value of $2,359,744.71. Following the sale, the chief executive officer now directly owns 677,887 shares in the company, valued at approximately $28,206,878.07. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In related news, CEO Yujiro S. Hata sold 56,711 shares of the stock in a transaction that occurred on Tuesday, May 14th. The stock was sold at an average price of $41.61, for a total transaction of $2,359,744.71. Following the sale, the chief executive officer now directly owns 677,887 shares in the company, valued at approximately $28,206,878.07. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Yujiro S. Hata sold 34,433 shares of the firm’s stock in a transaction on Thursday, May 16th. The shares were sold at an average price of $41.81, for a total value of $1,439,643.73. Following the sale, the chief executive officer now directly owns 677,887 shares of the company’s stock, valued at $28,342,455.47. The disclosure for this sale can be found here. Corporate insiders own 3.50% of the company’s stock.

About IDEAYA Biosciences

(Free Report)

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.

Featured Articles

Want to see what other hedge funds are holding IDYA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEAYA Biosciences, Inc. (NASDAQ:IDYAFree Report).

Institutional Ownership by Quarter for IDEAYA Biosciences (NASDAQ:IDYA)

Receive News & Ratings for IDEAYA Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEAYA Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.